Derosa Giuseppe, Maffioli Pamela
Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
Expert Rev Cardiovasc Ther. 2010 Jun;8(6):835-43. doi: 10.1586/erc.10.51.
Therapies that lower blood pressure or lipid levels slow the progression of atherosclerosis, and reduce morbidity and mortality in patients with hypertension or atherosclerotic disease. A combination tablet containing both amlodipine besylate and atorvastatin calcium has recently been approved for the treatment of hypertension and dyslipidemia in a growing number of countries. We decided to undertake a thorough literature search to evaluate the effects of amlodipine and atorvastatin in hypertensive hypercholesterolemic patients on blood pressure values, lipid profile values and, when available, data on small- and large-artery compliance, left ventricular mass index, and inflammatory parameters. From the data collected, it emerged that in hypertensive and hypercholesterolemic patients, the combination of amlodipine plus atorvastatin is more effective than the single drugs alone in reducing blood pressure and in improving lipid profile. Furthermore the combination of amlodipine plus atorvastatin also improved small-artery compliance, inflammatory markers, left ventricular hypertrophy and reduced uric acid faster and more effectively than the single drugs taken alone. For these reasons, the combination of amlodipine plus atorvastatin could be the treatment of choice in hypertensive and hypercholesterolemic patients.
降低血压或血脂水平的疗法可减缓动脉粥样硬化的进展,并降低高血压或动脉粥样硬化疾病患者的发病率和死亡率。一种含有苯磺酸氨氯地平和阿托伐他汀钙的复方片剂最近在越来越多的国家被批准用于治疗高血压和血脂异常。我们决定进行全面的文献检索,以评估氨氯地平和阿托伐他汀对高血压合并高胆固醇血症患者的血压值、血脂谱值的影响,以及在可获得数据时,对小动脉和大动脉顺应性、左心室质量指数和炎症参数的影响。从收集到的数据来看,在高血压合并高胆固醇血症患者中,氨氯地平加阿托伐他汀的联合用药在降低血压和改善血脂谱方面比单一药物更有效。此外,氨氯地平加阿托伐他汀的联合用药还比单一药物更快、更有效地改善了小动脉顺应性、炎症标志物、左心室肥厚,并降低了尿酸。基于这些原因,氨氯地平加阿托伐他汀的联合用药可能是高血压合并高胆固醇血症患者的首选治疗方法。